

Kidney Cancer GCOM 10 (day 2) minutes

Kidney Cancer update – committee meeting 10 (day 2) minutes

**Date:** 26/03/2025

**Location:** Virtual

**Minutes:** Final

**Committee members present:**

Baljit Singh	Chair	Present for items 1-7
Janet Brown	Medical Oncologist	Present for items 5-7
Amarnath Challapalli	Clinical Oncologist (General)	Present for items 1-7
Amy Clifford	Clinical Oncologist (SABR)	Present for items 1-7
John Connolly	Lay Member	Present for items 1-7
Stuart Evans	Oncology Pharmacist	Present for items 1-7
Geraldine Fox	Lay Member	Present for items 1-7
Fayiza Habeeb	Lead Nurse Practitioner	Present for items 1-7
David Mole	Nephrologist (co-opted member)	Present for items 2-7
Ankit Rao	Medical Oncologist	Present for items 1-7
Sandeep Singh Randhawa	General Practitioner	Present for items 1-7
Grant Stewart	Topic Adviser	Present for items 1-4
Tze Min Wah	Interventional Radiologist	Present for items 1-5
Sam Withey	Diagnostic Radiologist	Present for items 1-5
Rose Woodward	Lay member	Present for items 1-7

**In attendance NICE:**

Marie Harrisingh	Topic Lead	Present for items 1-7
Sarah Boyce	Senior Technical Analyst	Present for items 1-7
Danielle Conroy	Project Manager	Present for items 1-7
Lindsay Claxton	Health Economics Adviser	Present for items 1-7
Olivia Crane	Senior Technical Analyst	Present for items 1-7
Benjamin Gregory	Business Analyst, Resource Impact	Present for items 2-7
Gareth Haman	Senior Guidance Content Designer	Present for items 6-7
Lina Manounah	Technical Analyst	Present for items 1-7
Manon Owen	Coordinator, Methods and Economics (Observing)	Present for items 1-3, 5-7

Katherine Saxby	Medicines Adviser, Medicines Optimisation	Present for items 6-7
Hannah Tebbs	Senior Health Economist	Present for items 1-7
Ellie Zachariades	Senior Guidance Content Designer	Present for items 1-5

### Apologies:

Axel Bex	Urological Surgeon, Committee member
Lisa Browning	Histopathologist, Committee member
Victoria Carter	Implementation Support Manager, NICE
David Cullen	Urology Cancer Nurse, Committee member
Ana Semedo	Vice Chair, Oncology Cancer Nurse
Maxine Tran	Urological Surgeon, Committee member
Yuanyuan Zhang	Senior Health Economist, NICE

## 1. Welcome, Introductions and DOIs

The Chair, Baljit Singh (BS) welcomed the committee members and NICE attendees to day 2 of the 10th committee meeting for the NICE Kidney Cancer guideline.

BS informed attendees that apologies had been received as noted above. BS asked all committee members to verbally declare any new interests.

No new interests were declared but BS reminded the group of the following recorded interest which are relevant to the day's discussion:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Grant Stewart	Professor of Surgical Oncology, University of Cambridge, Honorary Consultant in Urological Surgery, Cambridge University Hospitals NHS Foundation	Dabestani, Saeed; Beisland, Christian; Stewart, Grant D; Bensalah, Karim; Gudmundsson, Eirikur; Lam, Thomas B; Gietzmann, William; Zakikhani, Paimaun; Marconi, Lorenzo; Fernandez-Pello, Sergio; Monagas, Serenella; Williams, Samuel P; Powles, Thomas; Van Werkhoven, Erik; Meijer, Richard; Volpe, Alessandro; Staehler, Michael; Ljungberg, Borje; Bex, Axel; Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results	Specific, Direct -non-financial professional and personal	Declare and partial exclusion  Participate in discussion but withdraw for drafting recommendations.

	Trust	from a European multicenter database (R.E.C.U.R.); Scandinavian journal of urology; 2019; vol. 53 (no. 1); 14-20		
Grant Stewart	Professor of Surgical Oncology, University of Cambridge, Honorary Consultant in Urological Surgery, Cambridge University Hospitals NHS Foundation Trust	Dabestani, Saeed; Beisland, Christian; Stewart, Grant D; Bensalah, Karim; Gudmundsson, Eirikur; Lam, Thomas B; Gietzmann, William; Zakikhani, Paimaun; Marconi, Lorenzo; Fernandez-Pello, Sergio; Monagas, Serenella; Williams, Samuel Paul; Torbrand, Christian; Powles, Thomas; Van Werkhoven, Erik; Meijer, Richard; Volpe, Alessandro; Staehler, Michael; Ljungberg, Borje; Bex, Axel; Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR).; European urology; 2019; vol. 75 (no. 2); 261-264	Specific, Direct -non-financial professional and personal	Specific  Participate in discussion but withdraw for drafting recommendations.
<p>Grant Stewart (GS) was an author on papers included in the evidence review being discussed. It was agreed that the member could stay for the discussion of the evidence for review question 5b, and to answer any questions but would need to step out whilst recommendations were being made.</p> <p>Finally, the minutes from committee 10 (day 1) were checked and agreed to be an accurate record.</p>				
<p><b>2. Revisiting recommendations:</b></p> <ul style="list-style-type: none"> <li><b>RQ5a - active surveillance</b></li> </ul>				
<p>The Chair introduced Marie Harrisingh (MH), Topic Lead who presented the previously drafted recommendations for active surveillance for further committee input. The committee had the opportunity to provide their expert input on several queries the NICE team had including revision to wording.</p> <p>BS thanked MH for her contribution.</p>				
<p><b>3. RQ5b (for adults who have had treatment for localised or locally advanced renal cell carcinoma, what are the most clinically and cost-effective risk-stratified follow-up strategies based on method, duration, and frequency):</b></p>				

- **Reminder of clinical evidence and previous discussions**
- **Reminder of equality and health inequality issues**

The Chair introduced Lina Manounah (LM), Technical Analyst who presented a summary of the clinical evidence for follow-up and monitoring for previously treated renal cell carcinoma. The committee were reminded of their earlier discussions of the evidence including their experience of current practice and any health inequality issues.

The committee had the opportunity to ask questions and input further on what was presented.

The Chair thanked LM for her presentation.

#### **4. RQ5b (for adults who have had treatment for localised or locally advanced renal cell carcinoma, what are the most clinically and cost-effective risk-stratified follow-up strategies based on method, duration, and frequency):**

- **Health economics modelling results**
- **Committee discussion**

The Chair introduced Lindsay Claxton (LC), Health Economics Adviser who presented the health economic modelling results for cost-effective follow-up strategies for monitoring long-term consequences of treatment and for early detection of recurrence or progression of the disease.

The committee had the opportunity to ask questions and discuss the evidence for this review question in it's entirety, including the key findings, if this reflected what is usually seen in clinical practice, how much confidence they had in the data included in the review and the key findings of the economic analysis.

#### **5. Drafting recommendations for RQ5b**

GS left the meeting at this point due to a conflict of interest.

Taking input from the committee to draft the initial wording, the NICE team were able to draft recommendations for follow-up strategies that would be taken away for further edits. This included recommendations for research in this area.

BS thanked the committee for their input.

#### **6. Visual summaries discussion**

The Chair introduced Katherine Saxby (KS), Medicines Adviser who presented the visual summaries for pharmacological treatment options for advanced renal cell carcinoma as outlined in NICE technology appraisals.

The committee had the opportunity to provide their expert input on first, second and

third-line treatments based on current clinical practice which would be taken away for further edits.

BS thanked KS for their presentation and committee for their input.

#### **7. Next steps and AOB**

BS summarised the main actions from the day and asked for items of any other business. As there was no further business to discuss, BS brought the meeting to a close.

**Date of next meeting:** 30/04/2025

**Location of next meeting:** Virtual